Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Communicable

Communicable artwork

Communicable E5 - Beauty is in the 'I' of the beholder: EUCAST updates

Jul 15, 202439 minAudio

The ‘I’ (intermediate susceptibility) in a EUCAST-guided antibiogram never meant impending resistance to your antibiotic. It was never meant to make you find the one ‘S’ (invariably a carbapenem) and use it instead - even if many clinicians did. In this episode of Communicable, hosts Marc Bonten and Angela Huttner welcome Profs. Christian Giske (outgoing chair) and Sören Gatermann (newly elected chair) of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) to discuss its recent updates, including the new ‘susceptible dose dependent’ (SDD) label, and to shed light on common misconceptions around the way it sets breakpoints. Breakpoints for Pseudomonas aeruginosa are discussed, as are intravenous fosfomycin’s ‘disappearance’ from the breakpoints table and EUCAST’s new guidance on it. Episode peer-reviewed by Dr. Suzanne van Asten of Radboud University Medical Center. Literature: The European Committee on Antimicrobial Susceptibility Testing (EUCAST): https://www.eucast.org/ EUCAST guidance on use of fosfomycin i.v. breakpoints: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Use_of_fosfomycin_iv_breakpoints_General_advice_20240528.pdf In vitro synergy between fosfomycin and ceftazidime/avibactam: Kroemer, Martens, Decousser et al. Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in Escherichia coli. J Antimicrob Chemother. 2023 Oct 3;78(10):2524-2534. doi: 10.1093/jac/dkad264

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Communicable E67: New antifungals & how to use them

    Nov 15, 202650 minAudio

    In this episode of Communicable, hosts Annie Joseph and Josh Nosanchuk welcome Neil Stone and Jeniel Nett to discuss new and emerging antifungal treatments, including ibrexafungerp, rezafungin and olorofim, among...

    Credit the people on this episode

  2. Communicable E66: Diagnostics in the AMR era

    Nov 1, 202651 minAudio

    Ahead of World Antimicrobial Resistance Awareness Week (WAAW), Communicable presents a special episode exploring the role of diagnostics within the space of antimicrobial resistance (AMR). Hosts Thomas Tängdén and Annie...

    Credit the people on this episode

  3. Communicable E65: Quarterly catch-up (October 2026 edition)

    Oct 18, 202649 minAudio

    In this episode of Communicable, Emily McDonald returns for another ‘Quarterly catch-up’ and is joined by Angela Huttner as co-host. Together, they review four recent randomised clinical trials, focusing on antibiotic...

    Credit the people on this episode

  4. Communicable E64: Getting micro on macrolides for community-acquired pneumonia

    Oct 4, 202650 minAudio

    In this episode of Communicable, hosts Emily McDonald and Marc Bonten are joined by Sylvain Lother and Valentijn Schweitzer for a discussion on the use of macrolides in community-acquired pneumonia. Together, they...

    Credit the people on this episode

  5. Communicable E63: Does oseltamivir harm critically ill patients? The REMAP-CAP results

    Sep 20, 20261 hr 3 minAudio

    At the Critical Care Reviews meeting in Belfast in June this year, REMAP-CAP investigators presented results suggesting that oseltamivir may be harmful in critically ill patients with influenza, upending a long-standing...

    Credit the people on this episode